Male Fertility-implications of anticancer treatment and strategies to mitigate gonadotoxicity

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 92-102

  Ragheb, Ahmed M ^a   Sabanegh Jr , Edmund S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHANE; METHOTREXATE; METHYLMETHANESULPHONATE; MITOMYCIN C; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; THIOTEPA; TROFOSFAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANEUPLOIDY; ASTHENOSPERMIA; AUTOTRANSPLANTATION; AZOOSPERMIA; BLOOD TESTIS BARRIER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHROMOSOME TRANSLOCATION; CRYOPRESERVATION; CYTOTOXICITY; DIPLOIDY; DISEASE SEVERITY; DISOMY; DNA DAMAGE; DNA FRAGMENTATION; DOMINANT LETHAL MUTANT; DRUG EFFECT; EMBRYO DEVELOPMENT; EWING SARCOMA; FERTILIZATION IN VITRO; GENE LOCUS; GENOME; GERM CELL; GERM CELL TUMOR; GONAD DYSFUNCTION; HAPLOIDY; HODGKIN DISEASE; HORMONAL THERAPY; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; KARYOTYPE; LEYDIG CELL; LIPID PEROXIDATION; MALE FERTILITY; MALE STERILITY; MICRONUCLEUS; MULTIPLE CYCLE TREATMENT; MUTAGENICITY; NONHODGKIN LYMPHOMA; OLIGOSPERMIA; PATIENT COUNSELING; PREGNANCY OUTCOME; PROGENY; RADIATION INJURY; REPRODUCTIVE TOXICITY; REVIEW; SEMEN ABNORMALITY; SEMEN ANALYSIS; SEMINIFEROUS TUBULE; SEMINOMA; SIDE EFFECT; SPERM; SPERM PRESERVATION; SPERMATOCYTE; SPERMATOGENESIS; SPERMATOGONIUM; SPERMATOZOON ABNORMALITY; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; STEM CELL; TERATOZOOSPERMIA; TESTIS CANCER; TESTIS DISEASE; TESTIS WEIGHT; XENOTRANSPLANTATION;

EID: 77950798023     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009010092     Document Type: Review

References (120)

1. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
2. Horner, M.J.R.L.; Krapcho, M.; Neyman, N.; Aminou, R.; Howlader, N.; Altekruse, S.F.; Feuer, E.J.; Huang, L.; Mariotto, A.; Miller, B.A.; Lewis, D.R.; Eisner, M.P.; Stinchcomb, D.G.; Edwards, B.K., Eds. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
3. Ries, L.A.G.; Eisner, M.P.; Kosary, C.L.; Hankey, B.F.; Miller, B.A.; Clegg, L.; Mariotto, A.; Fay, M.P.; Feuer, E.J.; Edwards, B.K. Eds. SEER Cancer Statistics Review, 1975-2000, National; Cancer Institute, Bethesda, MD, Available at: http://seer.cancer.gov/csr/1975-2000/, 2003.
4. Nalesnik, J.G.; Sabanegh, E.S., Jr.; Eng, T.Y.; Buchholz, T.A. Fertility in men after treatment for stage 1 and 2A seminoma. Am. J. Clin. Oncol., 2004, 27(6), 584-588.
5. Schover, L.R.; Brey, K.; Lichtin, A.; Lipshultz, L.I.; Jeha, S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J. Clin. Oncol., 2002, 20(7), 1880-1889.
6. Shetty, G.; Meistrich, M.L. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. J. Natl. Cancer Inst. Monogr., 2005, 34, 36-39.
7. Giwercman, A.; Petersen, P.M. Cancer and male infertility. Baillieres. Best Pract. Res. Clin. Endocrinol. Metab., 2000, 14(3), 453-471.
8. Meistrich, M.L. Critical components of testicular function and sensitivity to disruption. Biol. Reprod., 1986, 34(1), 17-28.
9. Aslam, I.; Fishel, S.; Moore, H.; Dowell, K.; Thornton, S. Fertility preservation of boys undergoing anti-cancer therapy: a review of the existing situation and prospects for the future. Hum. Reprod., 2000, 15(10), 2154-2159.
10. Hacker-Klom, U.B.; Meistrich, M.L.; Gohde, W. Effect of doxorubicin and 4'-epi-doxorubicin on mouse spermatogenesis. Mutat. Res., 1986, 160(1), 39-46.
11. Wyrobek, A.J.; Schmid, T.E.; Marchetti, F. Relative susceptibilities of male germ cells to genetic defects induced by cancer chemotherapies. J. Natl. Cancer Inst. Monogr., 2005, 34, 31-35.
12. O'Flaherty, C.; Hales, B.F.; Chan, P.; Robaire, B. Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity. Fertil. Steril., 2009.
13. Mitchell, R.T.; Saunders, P.T.; Sharpe, R.M.; Kelnar, C.J.; Wallace, W.H. Male fertility and strategies for fertility preservation following childhood cancer treatment. Endocr. Dev., 2009, 15, 101-134.
14. Evenson, D.P.; Arlin, Z.; Welt, S.; Claps, M.L.; Melamed, M.R. Male reproductive capacity may recover following drug treatment with the L-10 protocol for acute lymphocytic leukemia. Cancer, 1984, 53(1), 30-36.
15. Kenney, L.B.; Laufer, M.R.; Grant, F.D.; Grier, H.; Diller, L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer, 2001, 91(3), 613-621.
16. Meistrich, M.L.; Wilson, G.; Brown, B.W.; da Cunha, M.F.; Lipshultz, L.I. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer, 1992, 70(11), 2703-2712.
17. Oh, M.S.; Chang, M.S.; Park, W.; Kim do, R.; Bae, H.; Huh, Y.; Park, S.K. Yukmijihwang-tang protects against cyclophosphamideinduced reproductive toxicity. Reprod. Toxicol., 2007, 24(3-4), 365-370.
18. Thomson, A.B.; Campbell, A.J.; Irvine, D.C.; Anderson, R.A.; Kelnar, C.J.; Wallace, W.H. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet, 2002, 360(9330), 361-367.
19. Colpi, G.M.; Contalbi, G.F.; Nerva, F.; Sagone, P.; Piediferro, G. Testicular function following chemo-radiotherapy. Eur. J. Obstet. Gynecol. Reprod. Biol., 2004, 113 (Suppl 1), S2-6.
20. Tomomasa, H.; Oshio, S.; Ashizawa, Y.; Kamiyama, Y.; Okano, Y.; Iiyama, T.; Sato, S.; Shimizu, H.; Umeda, T. Gonadal function in patients with testicular germ cell tumors. Arch. Androl., 2002, 48(6), 405-415.
21. Petersen, P.M.; Giwercman, A.; Skakkebaek, N.E.; Rorth, M. Gonadal function in men with testicular cancer. Semin. Oncol., 1998, 25(2), 224-233.
22. Petersen, P.M.; Hansen, S.W.; Giwercman, A.; Rorth, M.; Skakkebaek, N.E. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann. Oncol., 1994, 5(4), 355-358.
23. Sanders, J.E.; Hawley, J.; Levy, W.; Gooley, T.; Buckner, C.D.; Deeg, H.J.; Doney, K.; Storb, R.; Sullivan, K.; Witherspoon, R.; Appelbaum, F.R. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood, 1996, 87(7), 3045-3052.
24. Meistrich, M.L.; Finch, M.; da Cunha, M.F.; Hacker, U.; Au, W.W. Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res., 1982, 42(1), 122-131.
25. Kuriyama, K.; Kitamura, T.; Yokoi, R.; Hayashi, M.; Kobayashi, K.; Kuroda, J.; Tsujii, H. Evaluation of testicular toxicity and sperm morphology in rats treated with methyl methanesulphonate (MMS). J. Reprod. Dev., 2005, 51(5), 657-667.
26. Kumar, S.G.; Narayana, K.; Bairy, K.L.; D'Souza, U.J.; Samuel, V.P.; Gopalakrishna, K. Dacarbazine induces genotoxic and cytotoxic germ cell damage with concomitant decrease in testosterone and increase in lactate dehydrogenase concentration in the testis. Mutat. Res., 2006, 607(2), 240-252.
27. Socie, G.; Salooja, N.; Cohen, A.; Rovelli, A.; Carreras, E.; Locasciulli, A.; Korthof, E.; Weis, J.; Levy, V.; Tichelli, A. Nonmalignant late effects after allogeneic stem cell transplantation. Blood, 2003, 101(9), 3373-3385.
28. Howell, S.J.; Shalet, S.M. Spermatogenesis after cancer treatment: damage and recovery. J. Natl. Cancer. Inst. Monogr., 2005, 34, 12-17.
29. O'Flaherty, C.; Vaisheva, F.; Hales, B.F.; Chan, P.; Robaire, B. Characterization of sperm chromatin quality in testicular cancer and Hodgkin's lymphoma patients prior to chemotherapy. Hum. Reprod., 2008, 23(5), 1044-1052. (Pubitemid 351757343)
30. Sieniawski, M.; Reineke, T.; Nogova, L.; Josting, A.; Pfistner, B.; Diehl, V.; Engert, A. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood, 2008, 111(1), 71-76.
31. Heikens, J.; Behrendt, H.; Adriaanse, R.; Berghout, A. Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease. Cancer, 1996, 78(9), 2020-2024.
32. Howell, S.J.; Radford, J.A.; Ryder, W.D.; Shalet, S.M. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J. Clin. Oncol., 1999, 17(5), 1493-1498.
33. Hobbie, W.L.; Ginsberg, J.P.; Ogle, S.K.; Carlson, C.A.; Meadows, A.T. Fertility in males treated for Hodgkins disease with COPP/ABV hybrid. Pediatr. Blood Cancer, 2005, 44(2), 193-196.
34. Petersen, P.M.; Skakkebaek, N.E.; Giwercman, A. Gonadal function in men with testicular cancer: biological and clinical aspects.APMIS, 1998, 106(1), 24-34; discussion 34-126
35. Spermon, J.R.; Ramos, L.; Wetzels, A.M.; Sweep, C.G.; Braat, D.D.; Kiemeney, L.A.; Witjes, J.A. Sperm integrity pre- and postchemotherapy in men with testicular germ cell cancer. Hum. Reprod., 2006, 21(7), 1781-1786.
36. Shafford, E.A.; Kingston, J.E.; Malpas, J.S.; Plowman, P.N.; Pritchard, J.; Savage, M.O.; Eden, O.B. Testicular function following the treatment of Hodgkin's disease in childhood. Br. J. Cancer, 1993, 68(6), 1199-1204.
37. Jacob, A.; Barker, H.; Goodman, A.; Holmes, J. Recovery of spermatogenesis following bone marrow transplantation. Bone Marrow Transplant., 1998, 22(3), 277-279.
38. Prahalathan, C.; Selvakumar, E.; Varalakshmi, P. Protective effect of lipoic acid on adriamycin-induced testicular toxicity. Clin. Chim. Acta, 2005, 360(1-2), 160-166. (Pubitemid 41225407)
39. Atessahin, A.; Turk, G.; Karahan, I.; Yilmaz, S.; Ceribasi, A.O.; Bulmus, O. Lycopene prevents adriamycin-induced testicular toxicity in rats. Fertil. Steril., 2006, 85 (Suppl 1), 1216-1222.
40. Dobrzynska, M.M.; Czajka, U.; Slowikowska, M.G. Reproductive effects after exposure of male mice to vincristine and to a combination of X-rays and vincristine. Reprod. Fertil. Dev., 2005, 17(8), 759-767.
41. Chatterjee, R.; Haines, G.A.; Perera, D.M.; Goldstone, A.; Morris, I.D. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum. Reprod., 2000, 15(4), 762-766.
42. Fossa, S.D.; Magelssen, H. Fertility and reproduction after chemotherapy of adult cancer patients: malignant lymphoma and testicular cancer. Ann. Oncol., 2004, 15 (Suppl 4), iv259-265.
43. Meistrich, M.L.; Wilson, G.; Mathur, K.; Fuller, L.M.; Rodriguez, M.A.; McLaughlin, P.; Romaguera, J.E.; Cabanillas, F.F.; Ha, C.S.; Lipshultz, L.I.; Hagemeister, F.B. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J. Clin. Oncol., 1997, 15(12), 3488-3495.
44. Rivkees, S.A.; Crawford, J.D. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA, 1988, 259(14), 2123-2125.
45. Mustieles, C.; Munoz, A.; Alonso, M.; Ros, P.; Yturriaga, R.; Maldonado, S.; Otheo, E.; Barrio, R. Male gonadal function after chemotherapy in survivors of childhood malignancy. Med. Pediatr. Oncol., 1995, 24(6), 347-351.
46. Rafsanjani, K.A.; Faranoush, M.; Hedayatiasl, A.A.; Vossough, P. Gonadal function and fertility in male survivors treated for Hodgkin's disease in Iran. Saud. Med. J., 2007, 28(11), 1690-1693.
47. Arnon, J.; Meirow, D.; Lewis-Roness, H.; Ornoy, A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum. Reprod. Update, 2001, 7(4), 394-403.
48. Vaisheva, F.; Delbes, G.; Hales, B.F.; Robaire, B. Effects of the chemotherapeutic agents for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome. J. Androl., 2007, 28(4), 578-587.
49. Huyghe, E.; Matsuda, T.; Daudin, M.; Chevreau, C.; Bachaud, J.M.; Plante, P.; Bujan, L.; Thonneau, P. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer, 2004, 100(4), 732-737.
50. Gaffan, J.; Holden, L.; Newlands, E.S.; Short, D.; Fuller, S.; Begent, R.H.; Rustin, G.J.; Seckl, M.J. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study. Br. J. Cancer, 2003, 89(10), 1849-1854.
51. De Mas, P.; Daudin, M.; Vincent, M.C.; Bourrouillou, G.; Calvas, P.; Mieusset, R.; Bujan, L. Increased aneuploidy in spermatozoa from testicular tumour patients after chemotherapy with cisplatin, etoposide and bleomycin. Hum. Reprod., 2001, 16(6), 1204-1208.
52. Stahl, O.; Eberhard, J.; Cavallin-Stahl, E.; Jepson, K.; Friberg, B.; Tingsmark, C.; Spano, M.; Giwercman, A. Sperm DNA integrity in cancer patients: the effect of disease and treatment. Int. J. Androl., 2008. [Epub ahead of print].
53. Morris, I.D. Sperm DNA damage and cancer treatment. Int. J. Androl., 2002, 25(5), 255-261.
54. Selvakumar, E.; Prahalathan, C.; Sudharsan, P.T.; Varalakshmi, P. Chemoprotective effect of lipoic acid against cyclophosphamideinduced changes in the rat sperm. Toxicology, 2006, 217(1), 71-78.
55. Ehling, U.H.; Neuhauser-Klaus, A. Induction of specific-locus and dominant lethal mutations in male mice by chlormethine. Mutat. Res., 1989, 227(2), 81-89. (Pubitemid 19242297)
56. Tiveron, C.; Russo, A.; Bassani, B.; Pacchierotti, F. Genotoxicity of trophosphamide in mouse germ cells: assessment of micronuclei in spermatids and chromosome aberrations in one-cell zygotes. Mutagenesis, 1996, 11(1), 125-130.
57. Rinchik, E.M.; Flaherty, L.; Russell, L.B. High-frequency induction of chromosomal rearrangements in mouse germ cells by the chemotherapeutic agent chlorambucil. Bioessays, 1993, 15(12), 831-836.
58. Russell, L.B.; Hunsicker, P.R.; Cacheiro, N.L.; Rinchik, E.M. Genetic, cytogenetic, and molecular analyses of mutations induced by melphalan demonstrate high frequencies of heritable deletions and other rearrangements from exposure of postspermatogonial stages of the mouse. Proc. Natl. Acad. Sci. USA, 1992, 89(13), 6182-6186.
59. Goldstein, L.S. Dominant lethal mutations induced in mouse spermatogonia by antineoplastic drugs. Mutat. Res., 1984, 140(4), 193-197.
60. Choudhury, R.C.; Jagdale, M.B.; Misra, S. Potential transmission of the cytogenetic effects of cisplatin in the male germline cells of Swiss mice. J. Chemother., 2000, 12(4), 352-359.
61. Ehling, U.H.; Adler, I.D.; Favor, J.; Neuhauser-Klaus, A. Induction of specific-locus and dominant lethal mutations in male mice by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl- 1-nitrosourea (CCNU). Mutat. Res., 1997, 379(2), 219-231.
62. Ehling, U.H.; Neuhauser-Klaus, A. Induction of specific-locus and dominant lethal mutations in male mice by busulfan. Mutat. Res., 1991, 249(2), 285-292.
63. Tates, A.D. Validation studies with the micronucleus test for early spermatids of rats. A tool for detecting clastogenicity of chemicals in differentiating spermatogonia and spermatocytes. Mutagenesis, 1992, 7(6), 411-419.
64. Adler, I.D.; Kliesch, U.; Jentsch, I.; Speicher, M.R. Induction of chromosomal aberrations by dacarbazine in somatic and germinal cells of mice. Mutagenesis, 2002, 17(5), 383-389.
65. Brandriff, B.F.; Meistrich, M.L.; Gordon, L.A.; Carrano, A.V.; Liang, J.C. Chromosomal damage in sperm of patients surviving Hodgkin's disease following MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) therapy with and without radiotherapy. Hum. Genet., 1994, 93(3), 295-299.
66. Martin, R.H.; Ernst, S.; Rademaker, A.; Barclay, L.; Ko, E.; Summers, N. Analysis of sperm chromosome complements before, during, and after chemotherapy. Cancer Genet. Cytogenet., 1999, 108(2), 133-136.
67. Russell, L.B.; Hunsicker, P.R.; Johnson, D.K.; Shelby, M.D. Unlike other chemicals, etoposide (a topoisomerase-II inhibitor) produces peak mutagenicity in primary spermatocytes of the mouse. Mutat. Res., 1998, 400(1-2), 279-286.
68. Attia, S.M.; Schmid, T.E.; Badary, O.A.; Hamada, F.M.; Adler, I.D. Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors. Mutat. Res., 2002, 520(1-2), 1-13.
69. Russell, L.B.; Hunsicker, P.R.; Kerley, M.K.; Johnson, D.K.; Shelby, M.D. Bleomycin, unlike other male-mouse mutagens, is most effective in spermatogonia, inducing primarily deletions. Mutat. Res., 2000, 469(1), 95-105.
70. Miller, B.M.; Adler, I.D. Aneuploidy induction in mouse spermatocytes. Mutagenesis, 1992, 7(1), 69-76.
71. Russell, L.B.; Hunsicker, P.R. Study of the base analog 6- mercaptopurine in the mouse specific-locus test. Mutat. Res., 1987, 176(1), 47-52.
72. Albanese, R. Mammalian male germ cell cytogenetics. Mutagenesis, 1987, 2(2), 79-85.
73. Frias, S.; Van Hummelen, P.; Meistrich, M.L.; Lowe, X.R.; Hagemeister, F.B.; Shelby, M.D.; Bishop, J.B.; Wyrobek, A.J. NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. Cancer Res., 2003, 63(1), 44-51.
74. Martin, R.H.; Rademaker, A.W.; Leonard, N.J. Analysis of chromosomal abnormalities in human sperm after chemotherapy by karyotyping and fluorescence in situ hybridization (FISH). Cancer Genet. Cytogenet., 1995, 80(1), 29-32.
75. Sudman, P.D.; Rutledge, J.C.; Bishop, J.B.; Generoso, W.M. Bleomycin: female-specific dominant lethal effects in mice. Mutat. Res., 1992, 296(1-2), 143-156.
76. Schmid, T.E.; Lowe, X.; Marchetti, F.; Bishop, J.; Haseman, J.; Wyrobek, A.J. Evaluation of inter-scorer and inter-laboratory reliability of the mouse epididymal sperm aneuploidy (m-ESA) assay. Mutagenesis, 2001, 16(3), 189-195.
77. Ehling, U.H.; Kratochvilova, J.; Lehmacher, W.; Neuhauser-Klaus, A. Mutagenicity testing of vincristine sulfate in germ cells of male mice. Mutat. Res., 1988, 209(3-4), 107-113.
78. Martin, R. Human sperm chromosome complements in chemotherapy patients and infertile men. Chromosoma, 1998, 107(6-7), 523-527.
79. Shelley, M.D.; Burgon, K.; Mason, M.D. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review. Cancer Treat. Rev., 2002, 28(5), 237-253.
80. Feldman, D.R.; Bosl, G.J.; Sheinfeld, J.; Motzer, R.J. Medical treatment of advanced testicular cancer. JAMA, 2008, 299(6), 672-684.
81. Lee, S.J.; Schover, L.R.; Partridge, A.H.; Patrizio, P.; Wallace, W.H.; Hagerty, K.; Beck, L.N.; Brennan, L.V.; Oktay, K. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol., 2006, 24(1), 2917-2931.
82. van der Kaaij, M.A.; Heutte, N.; Le Stang, N.; Raemaekers, J.M.; Simons, A.H.; Carde, P.; Noordijk, E.M.; Ferme, C.; Thomas, J.; Eghbali, H.; Kluin-Nelemans, H.C.; Henry-Amar, M. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol., 2007, 25(19), 2825-2832.
83. Wald, M.; Ross, L.S.; Prins, G.S.; Cieslak-Janzen, J.; Wolf, G.; Niederberger, C.S. Analysis of outcomes of cryopreserved surgically retrieved sperm for IVF/ICSI. J. Androl., 2006, 27(1), 60-65.
84. van Casteren, N.J.; van Santbrink, E.J.; van Inzen, W.; Romijn, J.C.; Dohle, G.R. Use rate and assisted reproduction technologies outcome of cryopreserved semen from 629 cancer patients. Fertil. Steril., 2008, 90(6), 2245-2250
85. Neal, M.S.; Nagel, K.; Duckworth, J.; Bissessar, H.; Fischer, M.A.; Portwine, C.; Tozer, R.; Barr, R.D. Effectiveness of sperm banking in adolescents and young adults with cancer: a regional experience. Cancer, 2007, 110(5), 1125-1129.
86. Schrader, M.; Muller, M.; Sofikitis, N.; Straub, B.; Krause, H.; Miller, K. "Onco-tese": testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines? Urology, 2003, 61(2), 421-425.
87. Salonia, A.; Gallina, A.; Matloob, R.; Rocchini, L.; Sacca, A.; Abdollah, F.; Colombo, R.; Suardi, N.; Briganti, A.; Guazzoni, G.; Rigatti, P.; Montorsi, F. Is sperm banking of interest to patients with nongerm cell urological cancer before potentially fertility damaging treatments? J. Urol., 2009, 182(3), 1101-1107.
88. Anderson, R.A.; Weddell, A.; Spoudeas, H.A.; Douglas, C.; Shalet, S.M.; Levitt, G.; Wallace, W.H. Do doctors discuss fertility issues before they treat young patients with cancer? Hum. Reprod., 2008, 23(10), 2246-2251
89. Goodwin, T.; Oosterhuis, E.B.; Kiernan, M.; Hudson, M.M.; Dahl, G.V. Attitudes and practices of pediatric oncology providers regarding fertility issues. Pediatr. Blood Cancer, 2007, 48(1), 80-85.
90. Schover, L.R.; Brey, K.; Lichtin, A.; Lipshultz, L.I.; Jeha, S. Oncologists' attitudes and practices regarding banking sperm before cancer treatment. J. Clin. Oncol., 2002, 20(7), 1890-1897.
91. Sutcliffe, A.G.; Taylor, B.; Saunders, K.; Thornton, S.; Lieberman, B.A.; Grudzinskas, J.G. Outcome in the second year of life after in vitro fertilisation by intracytoplasmic sperm injection: a UK casecontrol study. Lancet, 2001, 357(9274), 2080-2084.
92. Glaser, A.; Wilkey, O.; Greenberg, M. Sperm and ova conservation: existing standards of practice in North America. Med. Pediatr. Oncol., 2000, 35(2), 114-118.
93. A strategy for fertility services for survivors of childhood cancer. Hum. Fertil. (Camb), 2003, 6(2), A1-A39.
94. Achille, M.A.; Rosberger, Z.; Robitaille, R.; Lebel, S.; Gouin, J.P.; Bultz, B.D.; Chan, P.T. Facilitators and obstacles to sperm banking in young men receiving gonadotoxic chemotherapy for cancer: the perspective of survivors and health care professionals. Hum. Reprod., 2006, 21(12), 3206-3216.
95. Meistrich, M.L.; Wilson, G.; Huhtaniemi, I. Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. Cancer Res., 1999, 59(15), 3557-3560.
96. Kangasniemi, M.; Wilson, G.; Parchuri, N.; Huhtaniemi, I.; Meistrich, M.L. Rapid protection of rat spermatogenic stem cells against procarbazine by treatment with a gonadotropin-releasing hormone antagonist (Nal-Glu) and an antiandrogen (flutamide). Endocrinology, 1995, 136(7), 2881-2888.
97. Udagawa, K.; Ogawa, T.; Watanabe, T.; Yumura, Y.; Takeda, M.; Hosaka, M. GnRH analog, leuprorelin acetate, promotes regeneration of rat spermatogenesis after severe chemical damage. Int. J. Urol., 2001, 8(11), 615-622.
98. Ogawa, T.; Dobrinski, I.; Avarbock, M.R.; Brinster, R.L. Xenogeneic spermatogenesis following transplantation of hamster germ cells to mouse testes. Biol. Reprod., 1999, 60(2), 515-521. (Pubitemid 29063897)
99. Zhang Z, S.S.; Meistrich, M.L. The radiation-induced block in spermatogonial differentiation is due to damage to the somatic environment, not the germ cells. J. Cell. Physiol., 2007, 211, 149-158.
100. Keros, V.; Hultenby, K.; Borgstrom, B.; Fridstrom, M.; Jahnukainen, K.; Hovatta, O. Methods of cryopreservation of testicular tissue with viable spermatogonia in pre-pubertal boys undergoing gonadotoxic cancer treatment. Hum. Reprod., 2007, 22(5), 1384-1395.
101. Clouthier, D.E.; Avarbock, M.R.; Maika, S.D.; Hammer, R.E.; Brinster, R.L. Rat spermatogenesis in mouse testis. Nature, 1996, 381(6581), 418-421.
102. Nagano, M.; Patrizio, P.; Brinster, R.L. Long-term survival of human spermatogonial stem cells in mouse testes. Fertil. Steril., 2002, 78(6), 1225-1233.
103. Reis, M.M.; Tsai, M.C.; Schlegel, P.N.; Feliciano, M.; Raffaelli, R.; Rosenwaks, Z.; Palermo, G.D. Xenogeneic transplantation of human spermatogonia. Zygote, 2000, 8(2), 97-105.
104. Wyns, C.; Van Langendonckt, A.; Wese, F.X.; Donnez, J.; Curaba, M. Long-term spermatogonial survival in cryopreserved and xenografted immature human testicular tissue. Hum. Reprod., 2008, 23(11), 2402-2414.
105. Geens, M.; De Block, G.; Goossens, E.; Frederickx, V.; Van Steirteghem, A.; Tournaye, H. Spermatogonial survival after grafting human testicular tissue to immunodeficient mice. Hum. Reprod., 2006, 21(2), 390-396.
106. Schlatt, S.; Honaramooz, A.; Boiani, M.; Scholer, H.R.; Dobrinski, I. Progeny from sperm obtained after ectopic grafting of neonatal mouse testes. Biol. Reprod., 2003, 68(6), 2331-2335.
107. Lee, D.R.; Kim, K.S.; Yang, Y.H.; Oh, H.S.; Lee, S.H.; Chung, T.G.; Cho, J.H.; Kim, H.J.; Yoon, T.K.; Cha, K.Y. Isolation of male germ stem cell-like cells from testicular tissue of nonobstructive azoospermic patients and differentiation into haploid male germ cells in vitro. Hum. Reprod., 2006, 21(2), 471-476.
108. Nayernia, K.; Lee, J.H.; Lako, M.; Armstrong, L.; Herbert, M.; Li, M.; Engel, W.; Elliott, D.; Stojkovic, M.; Parrington, J.; Murdoch, A.; Strachan, T.; Zhang, X. In vitro derivation of human sperm from embryonic stem cells. Stem Cells Dev., 2009. [Epub ahead of print].
109. Selvakumar, E.; Prahalathan, C.; Sudharsan, P.T.; Varalakshmi, P. Protective effect of lipoic acid on cyclophosphamide-induced testicular toxicity. Clin. Chim. Acta, 2006, 367(1-2), 114-119.
110. Rezvanfar, M.; Sadrkhanlou, R.; Ahmadi, A.; Shojaei-Sadee, H.; Rezvanfar, M.; Mohammadirad, A.; Salehnia, A.; Abdollahi, M. Protection of cyclophosphamide-induced toxicity in reproductive tract histology, sperm characteristics, and DNA damage by an herbal source; evidence for role of free-radical toxic stress. Hum. Exp. Toxicol., 2008, 27(12), 901-910.
111. Tripathi, D.N.; Jena, G.B. Astaxanthin inhibits cytotoxic and genotoxic effects of cyclophosphamide in mice germ cells. Toxicology, 2008, 248(2-3), 96-103.
112. Padmanabhan, S.; Tripathi, D.N.; Vikram, A.; Ramarao, P.; Jena, G.B. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: intervention of folic and folinic acid. Mutat. Res., 2009, 673(1), 43-52.
113. Morris, I.D.; Ilott, S.; Dixon, L.; Brison, D.R. The spectrum of DNA damage in human sperm assessed by single cell gel electrophoresis (Comet assay) and its relationship to fertilization and embryo development. Hum. Reprod., 2002, 17(4), 990-998.
114. Ginsburg, E.S.; Yanushpolsky, E.H.; Jackson, K.V. In vitro fertilization for cancer patients and survivors. Fertil. Steril., 2001, 75(4), 705-710.
115. Brinkworth, M.H. Paternal transmission of genetic damage: findings in animals and humans. Int. J. Androl., 2000, 23(3), 123-135.
116. Fossa, S.D.; Magelssen, H.; Melve, K.; Jacobsen, A.B.; Langmark, F.; Skjaerven, R. Parenthood in survivors after adulthood cancer and perinatal health in their offspring: a preliminary report. J. Natl. Cancer Inst. Monogr., 2005, 34, 77-82.
117. Meistrich, M.L.; Byrne, J. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer treated with potentially mutagenic therapies Am. J. Hum. Genet., 2002, 70(4), 1069-1071.
118. Hyer, S.; Vini, L.; O'Connell, M.; Pratt, B.; Harmer, C. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin. Endocrinol. (Oxf), 2002, 56(6), 755-758.
119. Green, D.M.; Whitton, J.A.; Stovall, M.; Mertens, A.C.; Donaldson, S.S.; Ruymann, F.B.; Pendergrass, T.W.; Robison, L.L. Pregnancy outcome of partners of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol., 2003, 21(4), 716-721. (Pubitemid 46621908)
120. Winther, J.F.; Boice, J.D., Jr.; Mulvihill, J.J.; Stovall, M.; Frederiksen, K.; Tawn, E.J.; Olsen, J.H. Chromosomal abnormalities among offspring of childhood-cancer survivors in Denmark: a populationbased study. Am. J. Hum. Genet., 2004, 74(6), 1282-1285.